GlassScriptPhysician profile
Erin P Cox
NPI 1407213846
$1,485.81
in general payments reported to CMS, 2019-2025
19 companies · $77.62 in 2025
The $77.62 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.94 · 2022: $22.86 · 2023: $1,109 · 2024: $253 · 2025: $77.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $812 · Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $811.73 |
| Food and Beverage | $628.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $871.49 | 2023 | Iovera, Zilretta |
| Smith+Nephew, INC. | $84.59 | 2023-2025 | Healicoil, Collagenase Santyl |
| Melinta Therapeutics, LLC | $71.71 | 2024-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Stryker Corporation | $54.59 | 2021-2023 | Variax |
| Argentum Medical | $54.54 | 2023 | |
| Viiv Healthcare Company | $51.79 | 2024 | Dovato |
| Glaxosmithkline, LLC. | $44.91 | 2023-2024 | Nucala |
| Ossur Americas, INC. | $44.24 | 2024 | Miami J |
| Heron Therapeutics, INC. | $34.96 | 2023 | Zynrelef |
| Edwards Lifesciences Corporation | $25.78 | 2024 | Hemosphere |
| Genentech USA, INC. | $25.54 | 2025 | Xolair |
| Baudax Bio INC. | $22.86 | 2022 | |
| Aesculap, INC. | $21.35 | 2023 | Elan 4 |
| Phathom Pharmaceuticals, INC. | $16.67 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $14.51 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $14.32 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.89 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.69 | 2023 | |
| Dynasplint Systems INC. | $4.38 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.